drugset
drugset / Trial / NCT04649385

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

NCT04649385 ↗

Phase 1 Completed 157 enrolled BeiGene
Non-randomizedSequentialOpen-labelTreatment

Summary

The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone and in combination with tislelizumab in participants with advanced solid tumors.

Timeline

Start
2021-03-04
Primary completion
2025-10-17
Completion
2026-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject BGB-15025 Unknown — Oral
Subject Tislelizumab Monoclonal antibody 200 mg Intravenous
Background Capecitabine Small molecule — Intravenous
Background Carboplatin Small molecule — Intravenous
Background Cisplatin Other / unclassified — Intravenous
Background Nab-paclitaxel Small molecule — Intravenous
Background Oxaliplatin Small molecule — Intravenous
Background Paclitaxel Small molecule — Intravenous
Background Pemetrexed Small molecule — Intravenous

Indications

neoplasm